ARCH BIOPARTNERS INC (ARCH.CA) Fundamental Analysis & Valuation

TSX-V:ARCH • CA03938C1041

Current stock price

0.71 CAD
-0.02 (-2.74%)
Last:

This ARCH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ARCH.CA Profitability Analysis

1.1 Basic Checks

  • In the past year ARCH has reported negative net income.
  • In the past year ARCH has reported a negative cash flow from operations.
  • In the past 5 years ARCH always reported negative net income.
  • ARCH had negative operating cash flow in 4 of the past 5 years.
ARCH.CA Yearly Net Income VS EBIT VS OCF VS FCFARCH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1M -2M -3M -4M

1.2 Ratios

  • ARCH has a Return On Assets of -10783.60%. This is comparable to the rest of the industry: ARCH outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -10783.6%
ROE N/A
ROIC N/A
ROA(3y)-729.63%
ROA(5y)-491.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARCH.CA Yearly ROA, ROE, ROICARCH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K

1.3 Margins

  • ARCH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCH.CA Yearly Profit, Operating, Gross MarginsARCH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ARCH.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ARCH has more shares outstanding
  • The number of shares outstanding for ARCH has been increased compared to 5 years ago.
  • The debt/assets ratio for ARCH is higher compared to a year ago.
ARCH.CA Yearly Shares OutstandingARCH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ARCH.CA Yearly Total Debt VS Total AssetsARCH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

2.2 Solvency

  • ARCH has an Altman-Z score of -2293.69. This is a bad value and indicates that ARCH is not financially healthy and even has some risk of bankruptcy.
  • ARCH's Altman-Z score of -2293.69 is in line compared to the rest of the industry. ARCH outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2293.69
ROIC/WACCN/A
WACCN/A
ARCH.CA Yearly LT Debt VS Equity VS FCFARCH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M

2.3 Liquidity

  • ARCH has a Current Ratio of 0.01. This is a bad value and indicates that ARCH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ARCH has a Current ratio of 0.01. This is comparable to the rest of the industry: ARCH outperforms 50.00% of its industry peers.
  • A Quick Ratio of 0.01 indicates that ARCH may have some problems paying its short term obligations.
  • ARCH's Quick ratio of 0.01 is in line compared to the rest of the industry. ARCH outperforms 50.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
ARCH.CA Yearly Current Assets VS Current LiabilitesARCH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ARCH.CA Growth Analysis

3.1 Past

  • ARCH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.25%, which is quite impressive.
  • ARCH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -91.86%.
  • ARCH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.37% yearly.
EPS 1Y (TTM)28.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-91.86%
Revenue growth 3Y-34.11%
Revenue growth 5Y32.37%
Sales Q2Q%-100%

3.2 Future

  • ARCH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.22% yearly.
  • The Revenue is expected to grow by 170.06% on average over the next years. This is a very strong growth
EPS Next Y-131.43%
EPS Next 2Y19.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y248.78%
Revenue Next 5Y170.06%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARCH.CA Yearly Revenue VS EstimatesARCH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2028 2029 2030 50M 100M 150M 200M 250M
ARCH.CA Yearly EPS VS EstimatesARCH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

0

4. ARCH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARCH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARCH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCH.CA Price Earnings VS Forward Price EarningsARCH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCH.CA Per share dataARCH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04 -0.05

4.3 Compensation for Growth

  • ARCH's earnings are expected to grow with 19.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.22%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARCH.CA Dividend Analysis

5.1 Amount

  • ARCH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARCH.CA Fundamentals: All Metrics, Ratios and Statistics

ARCH BIOPARTNERS INC

TSX-V:ARCH (3/13/2026, 7:00:00 PM)

0.71

-0.02 (-2.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-02
Earnings (Next)05-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners17.86%
Ins Owner ChangeN/A
Market Cap47.52M
Revenue(TTM)158.10K
Net Income(TTM)-2.70M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 300.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10783.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-729.63%
ROA(5y)-491.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover6.32
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z -2293.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-131.43%
EPS Next 2Y19.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-91.86%
Revenue growth 3Y-34.11%
Revenue growth 5Y32.37%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y248.78%
Revenue Next 5Y170.06%
EBIT growth 1Y22.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.45%
EBIT Next 3Y89.45%
EBIT Next 5Y84.18%
FCF growth 1Y-216.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-216.37%
OCF growth 3YN/A
OCF growth 5YN/A

ARCH BIOPARTNERS INC / ARCH.CA Fundamental Analysis FAQ

What is the fundamental rating for ARCH stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARCH.CA.


Can you provide the valuation status for ARCH BIOPARTNERS INC?

ChartMill assigns a valuation rating of 0 / 10 to ARCH BIOPARTNERS INC (ARCH.CA). This can be considered as Overvalued.


How profitable is ARCH BIOPARTNERS INC (ARCH.CA) stock?

ARCH BIOPARTNERS INC (ARCH.CA) has a profitability rating of 0 / 10.